Infographics
-
Small Molecule Drug Substance Outsourcing Drivers
10/4/2022
ISR asked 57 respondents who outsource small molecule API which reason fits best with their company’s capacity for, and experience with, manufacturing small molecule drug substance. Read how the data shows the most common reason for outsourcing API manufacturing is a lack of capacity despite possessing in-house experience (42%).
-
Biologic Drug Substance Outsourcing Drivers
10/4/2022
ISR data from Q2 2022 shows the most common reason for outsourcing bioprocessing is a lack of capacity despite possessing in-house experience (41%).
-
Outsourced Bioprocessing By Respondent Location
9/13/2022
Europeans report outsourcing slightly more bioprocessing to China, while American respondents send more work to Japan and other Asia-Pacific manufacturing facilities (excluding China and India).
-
The Right Choice: Using Consultants For CDMO Selection
7/12/2022
In Q2 2022, ISR asked 99 outsourcers whether the company they work for uses consultants to help guide their CDMO selection process. Read the results from ISR’s CDMO Outsourcing Models (3rd Edition) to gain insight into the use of consultants during CDMO selection.
-
Drug Innovators’ Outlook On Innovative Treatments
6/14/2022
134 outsourcers of biologic drug substance provided insight into their pipelines are impactingoutsourcing practices. Two-thirds (63%) said a focus on new, innovative treatments will impact outsourcing decisions.
-
Reactor Technology’s Influence On CDMO Selection
5/4/2022
ISR asked 76 biopharma respondents that outsource commercialized products how much influence the contract manufacturer’s reactor technology has on their choice of CDMO.
-
Preference Among Users: New And Emerging Biopharma
4/13/2022
ISR asked new and emerging biopharma respondents which CDMOs they are currently working with, and, if the choice were entirely up to them, which CDMO would they prefer.
-
Use Of Preferred Providers Among Large Molecule Outsourcers
3/16/2022
ISR surveyed outsourcers of biologic API and outsourcers of biologics drug products to ask whether their company uses a preferred providers list of contract manufacturers for outsourced manufacturing.
-
Biologic Drug Product Outsourcing Drivers By Company Size
2/14/2022
The data show that sponsors from large pharma tend to use CMOs to augment internal manufacturing capacity (71%) while sponsors from non-large pharma use CMOs for all manufacturing needs (66%).
-
Large Molecule Drug Substance Pandemic Complications
1/14/2022
ISR asked respondents in its annual biologic drug substance benchmarking survey over the past two years whether they encountered pandemic related complications with their outsourced manufacturing. Learn why it was more common for large molecule drug substance outsourcers to experience COVID-19 related manufacturing complications in 2021 than during 2020.